Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.

@article{ArabAlameddine2014PopulationPM,
  title={Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.},
  author={Mona Arab-Alameddine and Rubin Lubomirov and Aur{\'e}lie Fayet-Mello and Manel Aouri and Margalida Rotger and Thierry Buclin and Nicolas Widmer and M Gatri and Bruno Ledergerber and Katharina M. Rentsch and Matthias Cavassini and Alice Panchaud and Monia Guidi and Amalio Telenti and Laurent A Decosterd and Chantal Csajka},
  journal={The Journal of antimicrobial chemotherapy},
  year={2014},
  volume={69 9},
  pages={2489-98}
}
OBJECTIVES Darunavir is a protease inhibitor that is administered with low-dose ritonavir to enhance its bioavailability. It is prescribed at standard dosage regimens of 600/100 mg twice daily in treatment-experienced patients and 800/100 mg once daily in naive patients. A population pharmacokinetic approach was used to characterize the pharmacokinetics of both drugs and their interaction in a cohort of unselected patients and to compare darunavir exposure expected under alternative dosage… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…